Juan Frias
Endocrinology, Diabetes & Metabolism · San Diego, CANPI 1134437601
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 51.6% of the total. Reporting peaked in 2019 at $557,222 and has fallen 98.1% since, to $10,501 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,111 payments — averaging $1295.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$743K
- Lilly USA, LLC$220K
- Merck$154K
- Novo Nordisk$74K
- Lifescan, Inc.$67K
- Novo Nordisk AS$59K
- plus $123K from 17 others
Across 3,431 payments — averaging $3939.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6.8M
- Sanofi US Services Inc.$2.1M
- Novo Nordisk AS$1.6M
- AbbVie$991K
- Pfizer$743K
- Boehringer Ingelheim$414K
- plus $910K from 14 others
What the payments were for
- Consulting fees$371,41826%
- Speaking & faculty fees$755,16952%
- Travel & lodging$293,82720%
- Food & beverage$16,9541%
- Education$2,2220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 328 | $743,073 |
| Lilly USA, LLC | 316 | $220,202 |
| Merck | 165 | $154,038 |
| Novo Nordisk | 77 | $74,163 |
| Lifescan, Inc. | 48 | $66,785 |
| Novo Nordisk AS | 30 | $58,631 |
| Eli Lilly | 85 | $52,694 |
| Echosens North America, Inc. | 9 | $15,895 |
| Corcept Therapeutics | 10 | $11,698 |
| Hikma Pharmaceuticals USA | 9 | $10,326 |
| Boehringer Ingelheim | 8 | $9,758 |
| BD | 4 | $6,186 |
| Pfizer | 4 | $4,440 |
| Dexcom, Inc. | 1 | $2,975 |
| Theratechnologies Inc. | 1 | $2,000 |
| Intercept Pharmaceuticals, Inc. | 1 | $1,820 |
| Valeritas, Inc. | 1 | $1,800 |
| Regeneron | 8 | $1,625 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $1,200 |
| Gilead | 2 | $143 |
| Abbott | 1 | $51 |
| Lexicon Pharmaceuticals, Inc. | 1 | $47 |
| Madrigal Pharmaceuticals | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$521,211
- TOUJEO$188,468
- MOUNJARO$169,398
- LANTUS$93,833
- STEGLATRO$62,178
- Victoza$34,594
- NO PRODUCT DISCUSSED$30,641
- AMARYL$27,785
- APIDRA$27,193
- INJECTABLES/PHARMA$27,193
- ADLYXIN$27,193
- SOTAGLIFLOZIN$22,669
- OneTouch$18,890
- FibroScan$15,895
- Ozempic$13,646
- OT Verio Reflect "One Touch Meter and Strips"$11,624
- Korlym$11,616
- JANUVIA$9,738
- DIABETES - DISEASE$6,829
- TRULICITY$5,600
How this compares
$1,439,591 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in San Diego
- Ken FujiokaSan Diego$747K
- Raymond PlodkowskiSan Diego$546K
- Jeremy PettusSan Diego$493K
- Samantha HarrisSan Diego$113K
- Suvesh ChandiokSan Diego$71K
- Schafer BoederSan Diego$60K
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.